A Single-center, Open-label, Phase Ib Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) With Different Dose in Healthy Adults Aged 18-70 Years in China
Latest Information Update: 05 May 2022
At a glance
- Drugs Staphylococcus aureus vaccine (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions
Most Recent Events
- 23 Apr 2022 Results published in the Vaccine
- 28 Mar 2021 Status changed from recruiting to completed.
- 31 May 2019 New trial record